Glaukos Corp (GKOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Glaukos Corp (GKOS) has a cash flow conversion efficiency ratio of -0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.53 Million) by net assets ($670.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Glaukos Corp to measure how much of total assets are equity-financed.
Glaukos Corp - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Glaukos Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Glaukos Corp's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Glaukos Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Glaukos Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dian Swastatika Sentosa Tbk
JK:DSSA
|
0.030x |
|
Inner Mongolia Yitai Coal Co Ltd
SHG:900948
|
0.043x |
|
Adani Total Gas Limited
NSE:ATGL
|
0.017x |
|
D-Wave Quantum Inc.
NYSE:QBTS
|
-0.040x |
|
Steel Authority of India Limited
NSE:SAIL
|
0.132x |
|
Ternium SA ADR
NYSE:TX
|
0.013x |
|
Bajaj Housing Finance
NSE:BAJAJHFL
|
-0.527x |
|
MOL NA A ADR REG.S 1/2
F:MOGG
|
0.046x |
Annual Cash Flow Conversion Efficiency for Glaukos Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of Glaukos Corp from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Glaukos Corp (GKOS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $656.15 Million | $-46.34 Million | -0.071x | +11.67% |
| 2024-12-31 | $766.93 Million | $-61.32 Million | -0.080x | +36.08% |
| 2023-12-31 | $461.77 Million | $-57.76 Million | -0.125x | -100.39% |
| 2022-12-31 | $530.00 Million | $-33.08 Million | -0.062x | -248.33% |
| 2021-12-31 | $587.15 Million | $24.71 Million | 0.042x | +222.18% |
| 2020-12-31 | $667.45 Million | $-22.99 Million | -0.034x | -6184.16% |
| 2019-12-31 | $673.27 Million | $-369.00K | -0.001x | -100.51% |
| 2018-12-31 | $173.86 Million | $18.86 Million | 0.109x | -41.21% |
| 2017-12-31 | $138.20 Million | $25.51 Million | 0.185x | +75.85% |
| 2016-12-31 | $117.27 Million | $12.31 Million | 0.105x | +556.64% |
| 2015-12-31 | $95.19 Million | $-2.19 Million | -0.023x | -152.04% |
| 2014-12-31 | $-160.90 Million | $-7.11 Million | 0.044x | -50.52% |
| 2013-12-31 | $-149.04 Million | $-13.30 Million | 0.089x | -96.09% |
| 2012-12-31 | $-8.95 Million | $-20.45 Million | 2.285x | -- |
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for a… Read more